The rapid pace in the evolution of knowledge regarding how cancer develops, and best approaches to treatment, is a challenge for the medical community. This educational activity will review the deleterious effects of DNA damage, specifically the science of homologous recombination deficiency and how it contributes to the development of cancer. Learn about approved and expanded indications for poly ADP-ribose polymerase (PARP) inhibitors, including evidence for their use based on biomarkers, efficacy, and safety data. The activity will include real-life case scenarios demonstrating how genetic testing data can be used to develop treatment plans.
Join us Monday, Dec. 4, from 11:30 a.m. to 1 p.m. PT, for the Midday Symposium Optimizing PARP Inhibitor Outcomes in Cancer Therapy: Focus on Biomarkers of Homologous Recombination Repair, held in room 157, 100 Level, Anaheim Convention Center North. Earn 1.5 hours of CE credit.
The Midday Symposium will also be broadcast as a live webinar for CE credit. If you have colleagues at home who are interested in this topic, encourage them to register for the webinar.
This activity is provided by ASHP and supported by educational grants from AstraZeneca and Merck.
